SG11202009036YA - Multivalent antibody - Google Patents

Multivalent antibody

Info

Publication number
SG11202009036YA
SG11202009036YA SG11202009036YA SG11202009036YA SG11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA
Authority
SG
Singapore
Prior art keywords
multivalent antibody
multivalent
antibody
Prior art date
Application number
SG11202009036YA
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Linda Johanna Aleida Hendriks
Ton Logtenberg
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202009036YA publication Critical patent/SG11202009036YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202009036YA 2018-03-30 2019-03-29 Multivalent antibody SG11202009036YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30
PCT/NL2019/050199 WO2019190327A2 (en) 2018-03-30 2019-03-29 Multivalent antibody

Publications (1)

Publication Number Publication Date
SG11202009036YA true SG11202009036YA (en) 2020-10-29

Family

ID=66349617

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009036YA SG11202009036YA (en) 2018-03-30 2019-03-29 Multivalent antibody

Country Status (18)

Country Link
US (3) US11952424B2 (https=)
EP (1) EP3774885A2 (https=)
JP (2) JP7603578B2 (https=)
KR (1) KR20200139189A (https=)
CN (1) CN111936514A (https=)
AR (1) AR115320A1 (https=)
AU (2) AU2019243665B2 (https=)
BR (1) BR112020019795A2 (https=)
CA (1) CA3094318A1 (https=)
EA (1) EA202091871A1 (https=)
IL (1) IL277672A (https=)
MA (1) MA52212A (https=)
MX (2) MX2020010267A (https=)
NZ (1) NZ767923A (https=)
PH (1) PH12020551504A1 (https=)
SG (1) SG11202009036YA (https=)
TW (1) TW202003569A (https=)
WO (1) WO2019190327A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
CA3124688A1 (en) * 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
JP7443376B2 (ja) 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
AU2020268684C1 (en) 2019-05-09 2026-04-02 Merus B.V. Variant domains for multimerizing proteins and separation thereof
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
IL294368A (en) 2020-01-29 2022-08-01 Merus Nv Means and method for modulating mixed effects in immune cells
WO2021200673A1 (ja) * 2020-03-31 2021-10-07 公立大学法人大阪 多重特異性抗体及びその製造方法
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
EP4149627A4 (en) * 2020-05-14 2024-05-29 The General Hospital Corporation POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
WO2021226984A1 (zh) 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
BR112022023697A2 (pt) 2020-05-21 2022-12-20 Merus Nv Métodos e meios para a produção de moléculas semelhantes a ig
AU2021378290B2 (en) * 2020-11-11 2025-10-30 Nautilus Subsidiary, Inc. Affinity reagents having enhanced binding and detection characteristics
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
CN119365490A (zh) * 2022-04-13 2025-01-24 Xencor股份有限公司 结合pd-l1、pd-l2和/或cd28的抗体
KR20250129720A (ko) 2022-12-27 2025-08-29 메뤼스 엔.페. 이중특이적 단백질을 생성하는 방법
WO2024144400A1 (en) * 2022-12-30 2024-07-04 Merus N.V. Promiscuous cd3 binding molecules
CN117946246B (zh) * 2023-02-23 2024-08-06 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2024206568A2 (en) * 2023-03-31 2024-10-03 Ibio, Inc. Anti-cd3 antibodies
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use
WO2025230409A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230410A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011084255A2 (en) 2009-12-17 2011-07-14 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2963696A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US9914777B2 (en) * 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
SMT202100230T1 (it) * 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
PT3433273T (pt) 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
MX2018013038A (es) * 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
SG11201809316XA (en) 2016-04-28 2018-11-29 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
ES2981272T3 (es) * 2016-09-23 2024-10-08 Merus Nv Moléculas de unión que modulan una actividad biológica expresada por una célula
CN110177805B (zh) 2016-10-19 2024-04-02 英温拉公司 抗体构建体
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
IL269656B2 (en) * 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
CN118027197A (zh) * 2017-07-06 2024-05-14 美勒斯公司 调节由细胞表达的生物活性的抗体
AU2018296067B2 (en) * 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
SG11202001050PA (en) * 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
JP7443376B2 (ja) * 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
AU2020268684C1 (en) * 2019-05-09 2026-04-02 Merus B.V. Variant domains for multimerizing proteins and separation thereof
IL293215A (en) * 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
IL294368A (en) * 2020-01-29 2022-08-01 Merus Nv Means and method for modulating mixed effects in immune cells

Also Published As

Publication number Publication date
WO2019190327A3 (en) 2019-11-14
US20190352401A1 (en) 2019-11-21
MA52212A (fr) 2021-02-17
JP2021519610A (ja) 2021-08-12
BR112020019795A2 (pt) 2021-01-05
US11952424B2 (en) 2024-04-09
MX2026002407A (es) 2026-04-01
AU2023222983A1 (en) 2023-09-21
CA3094318A1 (en) 2019-10-03
TW202003569A (zh) 2020-01-16
NZ767923A (en) 2024-11-29
KR20200139189A (ko) 2020-12-11
WO2019190327A8 (en) 2021-06-17
MX2020010267A (es) 2020-11-06
AU2019243665A1 (en) 2020-10-08
US20240352127A1 (en) 2024-10-24
AU2019243665B2 (en) 2023-06-01
IL277672A (en) 2020-11-30
JP7603578B2 (ja) 2024-12-20
EA202091871A1 (ru) 2021-06-22
US20240360217A1 (en) 2024-10-31
AR115320A1 (es) 2020-12-23
JP2024161509A (ja) 2024-11-19
CN111936514A (zh) 2020-11-13
PH12020551504A1 (en) 2021-09-13
WO2019190327A2 (en) 2019-10-03
EP3774885A2 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
IL277672A (en) Multivalent antibody
IL279321A (en) Anti-SIRPalpha antibody
IL280780A (en) Anti-TIGIT antibodies
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280013A (en) Anti-IL36R antibodies
IL278061A (en) Structures of antibodies against ROR
IL279352A (en) IL-11RA antibodies
GB201817172D0 (en) Antibody
IL278010A (en) Antibodies to galectin 10
SG11202106171WA (en) Anti-btla antibodies
IL277030A (en) Antibodies
ZA202101177B (en) Anti-btla antibody
ZA202108836B (en) Anti-epha4 antibody
GB201811368D0 (en) Antibody
IL273529A (en) Anti-PACAP antibody
SG11202102114UA (en) Anti-klrg1 antibodies
GB201806084D0 (en) Antibodies
GB201919062D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody
HK40040877A (en) Multivalent antibody
SG11202105718TA (en) Modified antibodies
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody
GB201912008D0 (en) Antibody
GB201819952D0 (en) Antibodies